Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists
US8642661B2 · kind B2 · utility
12Cited by
9References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 2, 2011 |
| Grant date | Feb 4, 2014 |
| Priority date | — |
| Expiry date | Oct 19, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Disclosed combinations include solabegron and oxybutynin. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.